---
title: "12 Health Care Stocks Moving In Thursday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291594082.md"
description: "During Thursday's after-market session, several healthcare stocks experienced significant volatility. Gainers included Seer (SEER) up 33.3% to $2.16, Universe Pharmaceuticals (UPC) up 14.08% to $7.21, and Orthofix Medical (OFIX) up 9.65% to $10.9. Conversely, losers featured Basel Medical Group (BMGL) down 12.3% to $7.32, SL Science Holding (SLBT) down 11.36% to $5.31, and Veraxa Biotech Holding (VRXA) down 9.32% to $1.85."
datetime: "2026-07-02T21:05:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291594082.md)
  - [en](https://longbridge.com/en/news/291594082.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291594082.md)
---

# 12 Health Care Stocks Moving In Thursday's After-Market Session

### Gainers

-   **Seer** (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million.
-   **Universe Pharmaceuticals** (NASDAQ:UPC) stock moved upwards by 14.08% to $7.21. The market value of their outstanding shares is at $3.6 million.
-   **Orthofix Medical** (NASDAQ:OFIX) stock rose 9.65% to $10.9. The company's market cap stands at $377.9 million.
-   **Bioventus** (NASDAQ:BVS) stock moved upwards by 6.01% to $11.11. The market value of their outstanding shares is at $666.2 million.
-   **Lixte Biotechnology Hldgs** (NASDAQ:LIXT) shares moved upwards by 4.85% to $7.56. The company's market cap stands at $133.3 million.
-   **Ensysce Biosciences** (NASDAQ:ENSC) stock moved upwards by 4.68% to $0.3. The company's market cap stands at $4.6 million.

### Losers

-   **Basel Medical Group** (NASDAQ:BMGL) shares decreased by 12.3% to $7.32 during Thursday's after-market session. The market value of their outstanding shares is at $11.0 million.
-   **SL Science Holding** (NASDAQ:SLBT) stock decreased by 11.36% to $5.31. The company's market cap stands at $2.4 billion.
-   **Veraxa Biotech Holding** (NASDAQ:VRXA) shares fell 9.32% to $1.85. The company's market cap stands at $243.9 million.
-   **AdaptHealth** (NASDAQ:AHCO) shares declined by 7.07% to $10.0. The market value of their outstanding shares is at $1.4 billion.
-   **CDT Equity** (NASDAQ:CDT) shares decreased by 6.85% to $0.46. The company's market cap stands at $2.5 million.
-   **OPKO Health** (NASDAQ:OPK) stock declined by 5.93% to $1.43. The company's market cap stands at $1.1 billion. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [SEER.US](https://longbridge.com/en/quote/SEER.US.md)
- [BMGL.US](https://longbridge.com/en/quote/BMGL.US.md)
- [UPC.US](https://longbridge.com/en/quote/UPC.US.md)
- [SLBT.US](https://longbridge.com/en/quote/SLBT.US.md)
- [OFIX.US](https://longbridge.com/en/quote/OFIX.US.md)
- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [BVS.US](https://longbridge.com/en/quote/BVS.US.md)
- [LIXT.US](https://longbridge.com/en/quote/LIXT.US.md)
- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [AHCO.US](https://longbridge.com/en/quote/AHCO.US.md)
- [CDT.US](https://longbridge.com/en/quote/CDT.US.md)
- [OPK.US](https://longbridge.com/en/quote/OPK.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)
- [CDTTW.US](https://longbridge.com/en/quote/CDTTW.US.md)

## Related News & Research

- [Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc. | SEER Stock News](https://longbridge.com/en/news/294094760.md)
- [Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting | SEER Stock News](https://longbridge.com/en/news/294117903.md)
- [Radoff-JEC group says it holds about 7.7% of Seer shares](https://longbridge.com/en/news/293671002.md)
- [Veraxa Biotech shareholders approved all proposals at extraordinary general meeting](https://longbridge.com/en/news/293793007.md)
- [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)